{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:06:21Z","timestamp":1784304381521,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chirurgie"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s00104-025-02277-0","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T07:55:00Z","timestamp":1743148500000},"page":"561-567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Update anaplastisches Schilddr\u00fcsenkarzinom\u00a0\u2013 Was ist f\u00fcr Chirurg*innen relevant?","Update on anaplastic thyroid cancer\u2014What is relevant for surgeons?"],"prefix":"10.1007","volume":"96","author":[{"given":"Sabine","family":"W\u00e4chter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef K.","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"issue":"3","key":"2277_CR1","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible\u00a0KC et\u00a0al (2021) 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31(3):337\u2013386. https:\/\/doi.org\/10.1089\/thy.2020.0944","journal-title":"Thyroid"},{"issue":"6","key":"2277_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clon.2010.03.013","volume":"22","author":"RC Smallridge","year":"2010","unstructured":"Smallridge\u00a0RC, Copland\u00a0JA (2010) Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol 22(6):486\u2013497. https:\/\/doi.org\/10.1016\/j.clon.2010.03.013","journal-title":"Clin Oncol"},{"issue":"8","key":"2277_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00761-021-00988-7","volume":"27","author":"V Arndt","year":"2021","unstructured":"Arndt\u00a0V, Dahm\u00a0S, Kraywinkel\u00a0K (2021) Krebspr\u00e4valenz in Deutschland 2017. Onkologe 27(8):717\u2013723. https:\/\/doi.org\/10.1007\/s00761-021-00988-7","journal-title":"Onkologe"},{"issue":"1","key":"2277_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ecl.2018.10.010","volume":"48","author":"AV Chintakuntlawar","year":"2019","unstructured":"Chintakuntlawar\u00a0AV, Foote\u00a0RL, Kasperbauer\u00a0JL, Bible\u00a0KC (2019) Diagnosis and management of anaplastic thyroid cancer. Endocrinol Metab Clin North Am 48(1):269\u2013284. https:\/\/doi.org\/10.1016\/j.ecl.2018.10.010","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"2277_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1530\/EJE-16-0574","volume":"175","author":"J Wendler","year":"2016","unstructured":"Wendler\u00a0J, Kroiss\u00a0M, Gast\u00a0K, Kreissl\u00a0MC, Allelein\u00a0S, Lichtenauer\u00a0U, Blaser\u00a0R, Spitzweg\u00a0C, Fassnacht\u00a0M, Schott\u00a0M, F\u00fchrer\u00a0D, Tiedje\u00a0V (2016) Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a\u00a0multicenter study in Germany. Eur J Endocrinol 175(6):521\u2013529. https:\/\/doi.org\/10.1530\/EJE-16-0574","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2277_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1007\/s00405-020-05853-8","volume":"277","author":"S W\u00e4chter","year":"2020","unstructured":"W\u00e4chter\u00a0S, Vorl\u00e4nder\u00a0C, Schabram\u00a0J, Mintziras\u00a0I, F\u00fclber\u00a0I, Manoharan\u00a0J, Holzer\u00a0K, Bartsch\u00a0DK, Maurer\u00a0E (2020) Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival. Eur Arch Otorhinolaryngol 277(5):1507\u20131514. https:\/\/doi.org\/10.1007\/s00405-020-05853-8","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"2","key":"2277_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/01.rlu.0000252240.35579.2c","volume":"32","author":"BD Nguyen","year":"2007","unstructured":"Nguyen\u00a0BD, Ram\u00a0PC (2007) PET\/CT staging and posttherapeutic monitoring of anaplastic thyroid carcinoma. Clin Nucl Med 32(2):145\u2013149","journal-title":"Clin Nucl Med"},{"issue":"7","key":"2277_CR8","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1089\/thy.2007.0350","volume":"18","author":"TV Bogsrud","year":"2008","unstructured":"Bogsrud\u00a0TV, Karantanis\u00a0D, Nathan\u00a0MA, Mullan\u00a0BP, Wiseman\u00a0GA, Kasperbauer\u00a0JL, Reading\u00a0CC, Hay\u00a0ID, Lowe\u00a0VJ (2008) 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid 18(7):713\u2013719","journal-title":"Thyroid"},{"issue":"12","key":"2277_CR9","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1007\/s00259-010-1570-6","volume":"37","author":"T Poisson","year":"2010","unstructured":"Poisson\u00a0T, Deandreis\u00a0D, Leboulleux\u00a0S, Bidault\u00a0F, Bonniaud\u00a0G, Baillot\u00a0S, Auperin\u00a0A, Al Ghuzlan\u00a0A, Travagli\u00a0JP, Lumbroso\u00a0J, Baudin\u00a0E, Schlumberger\u00a0M (2010) 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging 37(12):2277\u20132285","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2277_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00423-013-1057-6","volume":"398","author":"H Dralle","year":"2013","unstructured":"Dralle\u00a0H, Musholt\u00a0TJ, Schabram\u00a0J, Steinm\u00fcller\u00a0T, Frilling\u00a0A, Simon\u00a0D, Goretzki\u00a0PE, Niederle\u00a0B, Scheuba\u00a0C, Clerici\u00a0T, Hermann\u00a0M, Ku\u00dfmann\u00a0J, Lorenz\u00a0K, Nies\u00a0C, Schabram\u00a0P, Trupka\u00a0A, Zielke\u00a0A, Karges\u00a0W, Luster\u00a0M, Schmid\u00a0KW, Vordermark\u00a0D, Schmoll\u00a0HJ, M\u00fchlenberg\u00a0R, Schober\u00a0O, Rimmele\u00a0H, Machens\u00a0A (2013) German association of endocrine surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg 398(3):347\u2013375. https:\/\/doi.org\/10.1007\/s00423-013-1057-6","journal-title":"Langenbecks Arch Surg"},{"issue":"3","key":"2277_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s004230050205","volume":"384","author":"C Passler","year":"1999","unstructured":"Passler\u00a0C et\u00a0al (1999) Anaplastic (undifferentiated) thyroid carcinoma (ATC). A\u00a0retrospective analysis. Langenbeck\u2019s Arch Surg 384(3):284\u2013293","journal-title":"Langenbeck\u2019s Arch Surg"},{"issue":"13","key":"2277_CR12","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1245\/s10434-015-4742-6","volume":"22","author":"P Goffredo","year":"2015","unstructured":"Goffredo\u00a0P et\u00a0al (2015) Impact of timeliness of resection and thyroidectomy margin status on survival for patients with anaplastic thyroid cancer: an analysis of 335 cases. Ann Surg Oncol 22(13):4166\u20134174. https:\/\/doi.org\/10.1245\/s10434-015-4742-6","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"2277_CR13","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1002\/cncr.22203","volume":"107","author":"Y Wang","year":"2006","unstructured":"Wang\u00a0Y et\u00a0al (2006) Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 107(8):1786\u20131792. https:\/\/doi.org\/10.1002\/cncr.22203","journal-title":"Cancer"},{"key":"2277_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ejca.2016.02.015","volume":"59","author":"J Kwon","year":"2016","unstructured":"Kwon\u00a0J et\u00a0al (2016) The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: a\u00a0systematic review and meta-analysis. Eur J Cancer 59:34\u201345. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.015","journal-title":"Eur J Cancer"},{"issue":"9","key":"2277_CR15","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/cncr.30493","volume":"123","author":"TA Pezzi","year":"2017","unstructured":"Pezzi\u00a0TA et\u00a0al (2017) Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the national cancer data base. Cancer 123(9):1653\u20131661. https:\/\/doi.org\/10.1002\/cncr.30493","journal-title":"Cancer"},{"issue":"17","key":"2277_CR16","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1002\/cncr.28187","volume":"119","author":"MR Haymart","year":"2013","unstructured":"Haymart\u00a0MR et\u00a0al (2013) Marginal treatment benefit in anaplastic thyroid cancer. Cancer 119(17):3133\u20133139. https:\/\/doi.org\/10.1002\/cncr.28187","journal-title":"Cancer"},{"issue":"6","key":"2277_CR17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.surg.2010.09.011","volume":"148","author":"M Brauckhoff","year":"2010","unstructured":"Brauckhoff\u00a0M et\u00a0al (2010) Impact of extent of resection for thyroid cancer invading the aerodigestive tract on surgical morbidity, local recurrence, and cancer-specific survival. Surgery 148(6):1257\u20131266. https:\/\/doi.org\/10.1016\/j.surg.2010.09.011","journal-title":"Surgery"},{"issue":"3","key":"2277_CR18","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00405-023-07827-y","volume":"280","author":"E Maurer","year":"2023","unstructured":"Maurer\u00a0E, Eilsberger\u00a0F, W\u00e4chter\u00a0S, Riera Knorrenschild\u00a0J, Pehl\u00a0A, Holzer\u00a0K, Neubauer\u00a0A, Luster\u00a0M, Bartsch\u00a0DK (2023) Mutation-based, short-term \u201cneoadjuvant\u201d treatment allows resectability in stage IVB and C anaplastic thyroid cancer. Eur Arch Otorhinolaryngol 280(3):1509\u20131518. https:\/\/doi.org\/10.1007\/s00405-023-07827-y","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"1","key":"2277_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/thy.2009.0115","volume":"20","author":"T Higashiyama","year":"2010","unstructured":"Higashiyama\u00a0T et\u00a0al (2010) Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 20(1):7\u201314. https:\/\/doi.org\/10.1089\/thy.2009.0115","journal-title":"Thyroid"},{"issue":"4","key":"2277_CR20","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1089\/thy.2022.0504","volume":"33","author":"X Zhao","year":"2023","unstructured":"Zhao\u00a0X, Wang\u00a0JR, Dadu\u00a0R, Busaidy\u00a0NL, Xu\u00a0L, Learned\u00a0KO, Chasen\u00a0NN, Vu\u00a0T, Maniakas\u00a0A, Eguia\u00a0AA, Diersing\u00a0J, Gross\u00a0ND, Goepfert\u00a0R, Lai\u00a0SY, Hofmann\u00a0MC, Ferrarotto\u00a0R, Lu\u00a0C, Gunn\u00a0GB, Spiotto\u00a0MT, Subbiah\u00a0V, Williams\u00a0MD, Cabanillas\u00a0ME, Zafereo\u00a0ME (2023) Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: a\u00a0single-center retrospective cohort study. Thyroid 33(4):484\u2013491. https:\/\/doi.org\/10.1089\/thy.2022.0504","journal-title":"Thyroid"},{"issue":"5","key":"2277_CR21","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/cen.14679","volume":"96","author":"HC McCrary","year":"2022","unstructured":"McCrary\u00a0HC, Aoki\u00a0J, Huang\u00a0Y, Chadwick\u00a0B, Kerrigan\u00a0K, Witt\u00a0B, Hunt\u00a0JP, Abraham\u00a0D (2022) Mutation based approaches to the treatment of anaplastic thyroid cancer. Clin Endocrinol 96(5):734\u2013742. https:\/\/doi.org\/10.1111\/cen.14679","journal-title":"Clin Endocrinol"},{"issue":"6","key":"2277_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1200\/JOP.2016.012013","volume":"12","author":"ME Cabanillas","year":"2016","unstructured":"Cabanillas\u00a0ME, Zafereo\u00a0M, Gunn\u00a0GB, Ferrarotto\u00a0R (2016) Anaplastic thyroid carcinoma: treatment in the age of molecular targeted therapy. J\u00a0Oncol Pract 12(6):511\u2013518. https:\/\/doi.org\/10.1200\/JOP.2016.012013","journal-title":"J Oncol Pract"},{"key":"2277_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.014","author":"V Subbiah","year":"2022","unstructured":"Subbiah\u00a0V et\u00a0al (2022) Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase\u00a0II ROAR basket study. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014","journal-title":"Ann Oncol"},{"issue":"7","key":"2277_CR24","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2217\/fon-2018-0557","volume":"15","author":"S Takahashi","year":"2019","unstructured":"Takahashi\u00a0S et\u00a0al (2019) A Phase\u00a0II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer. Future Oncol 15(7):717\u2013726. https:\/\/doi.org\/10.2217\/fon-2018-0557","journal-title":"Future Oncol"},{"issue":"2","key":"2277_CR25","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3892\/mco.2019.1964","volume":"12","author":"H Iwasaki","year":"2020","unstructured":"Iwasaki\u00a0H et\u00a0al (2020) Lenvatinib vs. palliative therapy for stage IVC anaplastic thyroid cancer. Mol Clin Oncol 12(2):138\u2013143. https:\/\/doi.org\/10.3892\/mco.2019.1964","journal-title":"Mol Clin Oncol"},{"key":"2277_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/thy.2017.0285","volume":"28","author":"PC Iyer","year":"2018","unstructured":"Iyer\u00a0PC, Dadu\u00a0R, Ferrarotto\u00a0R et\u00a0al (2018) Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid 28:79\u201387","journal-title":"Thyroid"},{"key":"2277_CR27","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1089\/thy.2016.0627","volume":"27","author":"NM Iniguez-Ariza","year":"2017","unstructured":"Iniguez-Ariza\u00a0NM, Ryder\u00a0MM, Hilger\u00a0CR, Bible\u00a0KC (2017) Salvage lenvatinib therapy in metastatic anaplastic thyroid cancer. Thyroid 27:923\u2013927","journal-title":"Thyroid"},{"issue":"1","key":"2277_CR28","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1007\/s12020-019-01865-5","volume":"64","author":"S Cantara","year":"2019","unstructured":"Cantara\u00a0S et\u00a0al (2019) Blockade of the programmed death ligand\u00a01 (PD-L1) as potential therapy for anaplastic thyroid cancer. Endocrine 64(1):122\u2013129. https:\/\/doi.org\/10.1007\/s12020-019-01865-5","journal-title":"Endocrine"},{"key":"2277_CR29","doi-asserted-by":"publisher","DOI":"10.1089\/THY.2020.0322","author":"C Dierks","year":"2021","unstructured":"Dierks\u00a0C et\u00a0al (2021) The lenvatinib\/pembrolizumab combination is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. https:\/\/doi.org\/10.1089\/THY.2020.0322","journal-title":"Thyroid"},{"key":"2277_CR30","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack\u00a0SG et\u00a0al (2022) Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 186:631\u2013643. https:\/\/doi.org\/10.1530\/EJE-21-1259","journal-title":"Eur J Endocrinol"},{"key":"2277_CR31","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon\u00a0A, Laetsch\u00a0TW, Kummar\u00a0S et\u00a0al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N\u00a0Engl J Med 378:731\u2013739","journal-title":"N Engl J Med"},{"key":"2277_CR32","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","volume":"21","author":"RC Doebele","year":"2020","unstructured":"Doebele\u00a0RC, Drilon\u00a0A, Paz-Ares\u00a0L et\u00a0al (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase\u00a01\u20132\u00a0trials. Lancet Oncol 21:271\u2013282","journal-title":"Lancet Oncol"},{"key":"2277_CR33","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth\u00a0LJ, Sherman\u00a0E, Robinson\u00a0B et\u00a0al (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N\u00a0Engl J Med 383:825\u2013835","journal-title":"N Engl J Med"},{"key":"2277_CR34","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1158\/1078-0432.CCR-17-2297","volume":"24","author":"GJ Hanna","year":"2018","unstructured":"Hanna\u00a0GJ, Busaidy\u00a0NL, Chau\u00a0NG, Wirth\u00a0LJ, Barletta\u00a0JA, Calles\u00a0A, Haddad\u00a0RI, Kraft\u00a0S, Cabanillas\u00a0ME, Rabinowits\u00a0G et\u00a0al (2018) Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a\u00a0phase\u00a0II study. Clin Cancer Res 24:1546\u20131553. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2297","journal-title":"Clin Cancer Res"},{"key":"2277_CR35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3389\/fonc.2019.00106","volume":"9","author":"EJ Harris","year":"2019","unstructured":"Harris\u00a0EJ, Hanna\u00a0GJ, Chau\u00a0N, Rabinowits\u00a0G, Haddad\u00a0R, Margalit\u00a0DN, Schoenfeld\u00a0J, Tishler\u00a0RB, Barletta\u00a0JA, Nehs\u00a0M et\u00a0al (2019) Everolimus in anaplastic thyroid cancer: a\u00a0case series. Front Oncol 9:106. https:\/\/doi.org\/10.3389\/fonc.2019.00106","journal-title":"Front Oncol"}],"container-title":["Die Chirurgie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-025-02277-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00104-025-02277-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00104-025-02277-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T07:54:04Z","timestamp":1750924444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00104-025-02277-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2277"],"URL":"https:\/\/doi.org\/10.1007\/s00104-025-02277-0","relation":{},"ISSN":["2731-6971","2731-698X"],"issn-type":[{"value":"2731-6971","type":"print"},{"value":"2731-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"28 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0W\u00e4chter und D.K.\u00a0Bartsch geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieses Manuskript erf\u00fcllt die ethischen Standards f\u00fcr Forschung und Publikation. Alle Studien wurden gem\u00e4\u00df der Deklaration von Helsinki und mit entsprechender ethischer Genehmigung durchgef\u00fchrt. Informed Consent wurde, wo erforderlich, eingeholt.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}